Altimmune (NASDAQ:ALT) CEO Acquires $49,734.00 in Stock

Altimmune, Inc. (NASDAQ:ALT) CEO Jerome Durso acquired 30,700 shares of the company’s stock in a transaction that occurred on Friday, November 13th. The stock was bought at an average cost of $1.62 per share, with a total value of $49,734.00. Following the purchase, the chief executive officer owned 93,200 shares in the company, valued at $150,984. The trade was a 49.12% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Altimmune Price Performance

Shares of NASDAQ ALT traded up $0.04 during midday trading on Friday, reaching $1.66. 3,501,696 shares of the company were exchanged, compared to its average volume of 4,245,085. The stock’s 50-day moving average price is $2.62 and its 200-day moving average price is $3.17. The stock has a market cap of $321.93 million, a P/E ratio of -2.12 and a beta of 0.16. Altimmune, Inc. has a one year low of $1.58 and a one year high of $6.44. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). On average, sell-side analysts anticipate that Altimmune, Inc. will post -0.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently made changes to their positions in the stock. Cetera Investment Advisers increased its stake in shares of Altimmune by 19.4% in the first quarter. Cetera Investment Advisers now owns 35,453 shares of the company’s stock valued at $109,000 after buying an additional 5,766 shares during the period. Vontobel Holding Ltd. raised its position in shares of Altimmune by 23.1% during the third quarter. Vontobel Holding Ltd. now owns 30,787 shares of the company’s stock worth $88,000 after acquiring an additional 5,787 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Altimmune by 26.0% in the first quarter. The Manufacturers Life Insurance Company now owns 34,763 shares of the company’s stock worth $107,000 after acquiring an additional 7,167 shares during the period. Parallel Advisors LLC lifted its stake in shares of Altimmune by 21,755.0% in the third quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock worth $25,000 after acquiring an additional 8,702 shares during the period. Finally, AXQ Capital LP lifted its stake in shares of Altimmune by 19.0% in the second quarter. AXQ Capital LP now owns 56,810 shares of the company’s stock worth $173,000 after acquiring an additional 9,058 shares during the period. Institutional investors own 78.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Evercore reiterated an “outperform” rating on shares of Altimmune in a research report on Wednesday, September 23rd. HC Wainwright restated a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. Finally, B. Riley Financial reiterated a “buy” rating on shares of Altimmune in a research report on Friday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Altimmune currently has an average rating of “Moderate Buy” and an average target price of $14.33.

Key Stories Impacting Altimmune

These are some of the ALT stories that stood out recently:

• Positive Sentiment: New 48-week Phase 2b IMPACT data showed significant improvements in measures of liver fat, inflammation and fibrosis, alongside weight loss and generally favorable tolerability for investigational pemvidutide in MASH. The results were published in The Lancet Gastroenterology & Hepatology and support the ongoing Phase 3 PERFORMA trial. Article
• Positive Sentiment: Altimmune reported $480 million in cash, cash equivalents and investments at September 30, with a stated runway through the PERFORMA readout and into 2029—an important buffer for its clinical programs. Article
• Positive Sentiment: B. Riley reaffirmed its “buy” rating, signaling continued analyst support. Article

Altimmune Company Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.